



*Elect/Amend A/#7*  
Docket No.: PC-0049 CIP  
*J 1.14.03*

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Box Non-Fee Amendment** Commissioner for Patents, Washington, D.C. 20231 on December 17, 2002.

By: *[Signature]* Printed: Margaret M. Hasson

**RECEIVED**

DEC 31 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**TECH CENTER 1600/2900**

In re Application of: **Goold et al.**

Title: **TUMOR SUPPRESSOR**

Serial No.: **09/924,654**

Filing Date: **August 07, 2001**

Examiner: **To Be Assigned**

Group Art Unit: **1642**

**Box Non-Fee Amendment**  
Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121**

Sir:

This paper is responsive to the Restriction Requirement and Request for Election dated December 4, 2002, setting a 30-day or one (1) month term for response. Prior to examination of the application, please amend the specification of the above-identified application as listed below.

**IN THE SPECIFICATION**

Please replace the paragraph beginning at page 12, line 35, with the following rewritten paragraph(s):

*A1*  
cDNAs encoding the tumor suppressor were identified using BLAST2 with default parameters and the ZOOSEQ databases (Incyte Genomics, Palo Alto CA). These cDNAs have from about 88% to about 96% sequence identity to the cDNA encoding the human protein as shown in the table below. The first column shows the SEQ ID<sub>H</sub> for the human cDNA; the second column, the SEQ ID<sub>FR</sub> for fragment cDNAs; the third column, the sequence numbers for the fragments; the fourth column, the